P53, GHRH, inflammation and cancer
Open Access
- 1 November 2018
- journal article
- review article
- Published by Elsevier in EBioMedicine
- Vol. 37, 557-562
Abstract
No abstract availableKeywords
Funding Information
- Louisiana State University Shreveport
- College of Arts, Education, and Sciences, University of Louisiana Monroe
- National Institutes of Health (5 P20 GM103424-15, 3 P20 GM103424-15S1)
- National Institute of General Medical Sciences
This publication has 75 references indexed in Scilit:
- STAT3 negatively regulates thyroid tumorigenesisProceedings of the National Academy of Sciences, 2012
- Mutant p53 Gain-of-Function in CancerCold Spring Harbor Perspectives in Biology, 2009
- The CDK domain of p21 is a suppressor of IL‐1β‐mediated inflammation in activated macrophagesEuropean Journal of Immunology, 2009
- Antioxidant activity of growth hormone-releasing hormone antagonists in LNCaP human prostate cancer lineProceedings of the National Academy of Sciences, 2008
- Cancer related inflammation: The macrophage connectionCancer Letters, 2008
- Cancer-related inflammationNature, 2008
- Knocking down gene expression for growth hormone-releasing hormone inhibits proliferation of human cancer cell linesBritish Journal of Cancer, 2008
- Vascular permeability, vascular hyperpermeability and angiogenesisAngiogenesis, 2008
- Loss of p53 promotes RhoA–ROCK-dependent cell migration and invasion in 3D matricesJournal of Cell Biology, 2007
- Cell cycle regulator E2F1 modulates angiogenesis via p53-dependent transcriptional control of VEGFProceedings of the National Academy of Sciences, 2006